Slaughter and May is advising Hikma on its acquisition of Roxane
Slaughter and May is advising Hikma Pharmaceuticals PLC ('Hikma') on its acquisition of Roxane from Boehringer Ingelheim ('BI').
The acquisition values Roxane at approximately US$2.65 billion.
Under the acquisition, on closing Hikma will pay cash consideration of US$1.18 billion and will issue 40 million new Hikma shares to BI. Hikma has also agreed to make contingent cash payments of up to US$125 million, subject to the achievement of certain performance milestones.